ArticleScientific reports2025
Effect of adding gonadotropin-releasing hormone agonists for luteal support in antagonist cycles on pregnancy outcomes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This retrospective cohort study evaluated whether gonadotropin-releasing hormone agonists (GnRHa) used for luteal support during antagonist cycles improved pregnancy outcomes in patients undergoing fresh embryo transfer. We examined 3,115 patients who underwent antagonist-protocol in vitro fertilization and embryo transfers between February 2022 and December 2023. We compared a group that received luteal support with GnRHa (n = 262) with a conventional support group (n = 2,853). Prior to propensity score matching (PSM), the GnRHa group demonstrated a significantly higher clinical pregnancy rate (59.54%) than the conventional group (53.80%; p = 0.042); this rate remained significant after PSM (p = 0.026). The GnRHa group with progesterone levels < 1.0 ng/ml on the day of administration exhibited significantly higher clinical pregnancy rates than the conventional group (64.88% vs. 53.73%, respectively; p = 0.020). Similarly, patients undergoing fresh single blastocyst transfer who received GnRHa demonstrated significantly higher clinical pregnancy, implantation, and live birth rates (67.57%, 56.76%, and 48.65%, respectively) than those in the conventional group (p = 0.003 0.024, and 0.036, respectively). The results of this study showed that the introduction of GnRHa during fresh embryo transfer for patients undergoing antagonist cycles strengthened luteal support and improved clinical pregnancy rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.